Charlotte Plasma Cell Disorder Congress | Conference

Dr. Munshi on Testing for MRD in Multiple Myeloma

March 21st 2020

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses ways to test for minimal residual disease (MRD) in multiple myeloma.

Dr. Kumar on Ongoing Research in Multiple Myeloma

March 21st 2020

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses ongoing research in multiple myeloma.

Dr. Hillengass on Imaging Modalities in Multiple Myeloma

March 20th 2020

Jens Hillengass, MD, discusses available imaging modalities in multiple myeloma.

Dr. Hari on Misconceptions Regarding Allogeneic Stem Cell Transplant in Multiple Myeloma

March 19th 2020

Parameswaran Hari, MD, MRCP, discusses misconceptions regarding allogeneic stem cell transplant in multiple myeloma.

Preventing Progression and Chasing Cure in Smoldering Myeloma

August 14th 2019

Data from several clinical trials support treatment with lenalidomide (Revlimid) plus low-dose dexamethasone in select patients with high-risk smoldering multiple myeloma to prevent disease progression and other promising combinations under investigation are showing curative potential.

Combinations Mark Future of Immunotherapy in Multiple Myeloma

August 14th 2019

The emergence of monoclonal antibodies, immunomodulatory agents, immunotoxins, bispecific T-cell engagers, and CAR T-cell therapies will redefine multiple myeloma treatment. However, these new approaches, by themselves, are not enough to achieve cure; they must be used in combination.

Dr. Rodriguez on Evolving Role of Small Molecules in Multiple Myeloma

August 14th 2019

Cesar Rodriguez Valdes, MD, assistant professor of Hematology and Oncology, Wake Forest University Comprehensive Cancer Center, highlights the evolving role of small molecules in multiple myeloma.

Dr. Castillo on Emerging Treatment Approaches in Waldenstrom Macroglobulinemia

August 14th 2019

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, highlights ongoing research with emerging treatment approaches in Waldenström macroglobulinemia.

Multiagent Regimens Continue to Spearhead Progress in Late Relapsed Myeloma

August 14th 2019

Peter Voorhees, MD, discusses the recent data with triplet regimens in late relapsed multiple myeloma and other novel agents shaking up the paradigm.

Novel Induction Regimens Boost Survival in Newly Diagnosed Myeloma

August 13th 2019

The goal of induction regimens for patients with newly diagnosed multiple myeloma is to reduce the burden of disease and prolong durability of response and overall survival, while minimizing toxicity.